NCT05204368尚未招募3 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40)
Evopoint Biosciences Inc.1 个研究点 分布在 1 个国家目标入组 780 人开始时间: 2023年3月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 780
- 试验地点
- 1
- 主要终点
- overall success
研究概览
简要总结
This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients willing and able to provide written informed consent.
- •Willing and able to comply with all study assessments and adhere to the protocol schedule.
- •Hospitalized or requiring hospitalization for cUTI or AP in male or female patients ≥18 years on the day of signing informed consent.
- •Requiring treatment with IV antibiotic therapy.
- •Evidence of AP or cUTI
- •At least 1 of the following:
- •Nausea or vomiting.
- •Chills or rigors or warmth associated with fever (temperature >38°C).
- •Peripheral white blood cell count (WBC) >10,000/mm³ or bandemia , regardless of WBC count.
- •Having at least 1 of the following complicated factors for cUTI (not required for AP):
- •Indwelling catheter of the urinary tract.
- •Urinary retention.
- •Any functional or anatomical abnormality of the urogenital tract resulting in at least 100 mL or more of residual urine after voiding.
- •Obstructive uropathy .
- •Evidence of pyuria demonstrated by 1 of the following methods:
- •Dipstick analysis positive for leukocyte esterase.
- •≥10 WBCs per µL in unspun urine, or ≥10 WBCs per high power field in spun urine.
排除标准
- •Patients with any of the following conditions:
- •Suspected or confirmed perinephric abscess
- •Suspected or confirmed renal corticomedullary abscess
- •Suspected or confirmed acute or chronic bacterial prostatitis, orchitis, or epididymitis, as determined by history and/or physical examination
- •Known polycystic kidney disease or only 1 functional kidney
- •Known chronic vesicoureteral reflux
- •Previous renal transplantation or planned renal transplantation within 2 weeks of study entry
- •Patients receiving renal replacement therapy
- •Complete, permanent obstruction of the urinary tract
- •Urinary tract symptoms attributable to a sexually transmitted disease.
- •Gross hematuria requiring intervention other than administration of study drug.
- •Urinary tract surgery within 7 days prior to randomization or urinary tract surgery planned during the study period (except surgery required to relieve an obstruction or place a stent or nephrostomy).
- •Patient has any urinary catheter or device that will not be removed or replaced (if removal is not clinically acceptable) during IV therapy, including but NOT limited to indwelling bladder catheters, ureteral catheters, suprapubic catheters, J stents, and nephrostomy tubes.
- •Renal function at Screening as estimated glomerular filtrated rate <15 mL/min/1.73㎡, calculated using Modification of Diet in Renal Disease.
- •Known non-urinary tract source of infection such as endocarditis, osteomyelitis, abscess, meningitis, or pneumonia diagnosed within 7 days prior to randomization.
- •Any rapidly progressing disease or immediately life-threatening illness, including, but not limited to, current or impending respiratory failure, septic shock, acute heart failure, acute coronary syndrome, unstable arrhythmias, hypertensive emergency, acute hepatic failure, active gastrointestinal bleeding, profound metabolic abnormalities (e.g., diabetic ketoacidosis), or acute cerebrovascular events.
- •If the culture result is available prior to randomization and identifies only a Gram-positive pathogen and/or only a Gram negative pathogen (>10^5 CFU/mL) known to be resistant to meropenem
- •If the culture result is available prior to randomization and identifies isolates >2 pathogens or no pathogens with >10^5 CFU/mL identified or patient has a confirmed fungal UTI.
- •Receipt of more than 24 hours of a potentially effective systemic antibacterials within 72 hours prior to start of study therapy.
- •History of a seizure disorder.
- •Female patients of childbearing potential, who are unable or unwilling to use a highly effective method of birth control during the study and for at least 30 days following the last dose of study medication.
- •A female who is pregnant or breastfeeding, or have a positive pregnancy test at Screening.
- •Patient is participating in any clinical study of any investigational medication (i.e., non-licensed medication) during the 30 days prior to randomization. COVID-19 vaccines that are given under emergency use authorization are not considered investigational agents.
- •Documented presence of immunodeficiency or an immunocompromised condition including hematologic malignancy, bone marrow transplant, known human immunodeficiency virus infection with a CD4 count <200/mm³, or requiring frequent or prolonged use of systemic corticosteroids or other immunosuppressive drugs.
- •Patients with 1 or more of the following laboratory abnormalities in baseline specimens: aspartate aminotransferase, alanine aminotransferase >3 × the upper limit of normal (ULN), total bilirubin level >2 × ULN (except for isolated hyperbilirubinemia due to known Gilbert's disease), neutrophils <500 cells/mm³, platelet count <40,000/mm³
- •Patients requires concomitant medication with valproic acid or divalproex.
- •History of active liver disease, cirrhosis.
- •Documented or severe hypersensitivity or previous severe adverse drug reaction, especially to any beta-lactam antibiotics, or any of the excipients used in the study drug formulations.
- •Any other condition or prior therapy, which, in the opinion of the investigator, would make the patient unsuitable for this study.
研究组 & 干预措施
Imipenem/Cilastatin/XNW4107
Experimental
Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg ,q6h(0.5h infusion)
干预措施: Combination of Imipenem/Cilastatin and XNW4107 (Drug)
Meropenem
Active Comparator
Meropenem 1g ,q8h (0.5h infusion)
干预措施: Meropenem (Drug)
结局指标
主要结局
overall success
时间窗: Day 21[±2 days]
The proportion of patients who achieve overall success at the Test of cure(TOC) visit in the micro-modified-intent-to-treat(micro-MITT) population. Overall success requires symptomatic clinical success and microbiologic success at the TOC visit.
次要结局
- overall success(Day 28[±3 days])
- symptomatic clinical success(Day 4; EOT: from treatment day 7 up to day 15; TOC: Day 21[±2 days]; LFU: Day 28[±3 days])
- microbiological success(EOT: from treatment day 7 up to day 15; TOC: Day 21[±2 days]; LFU: Day 28[±3 days])
- By-pathogen microbiological success(EOT: from treatment day 7 up to day 15; TOC: Day 21[±2 days]; LFU: Day 28[±3 days])
- The proportion of overall success; symptomatic clinical, and microbiologic success(EOT: from treatment day 7 up to day 15; TOC: Day 21[±2 days]; LFU: Day 28[±3 days])
- clinical success(Day 21[±2 days])
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter PyloriHelicobacter Pylori InfectionNCT05577468Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.561
已完成
3 期
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) InhibitorsUlcerative ColitisNCT02136069Hoffmann-La Roche397
已完成
3 期
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal InfectionsComplicated Intra-abdominal InfectionsComplicated AppendicitisNCT02784704Tetraphase Pharmaceuticals, Inc.500
已完成
3 期
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal InfectionsComplicated Intra-abdominal InfectionsNCT01844856Tetraphase Pharmaceuticals, Inc.541
已完成
3 期
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract InfectionscUTINCT01978938Tetraphase Pharmaceuticals, Inc.908